SynthesisFrontiers in psychiatry2023
Stanford neuromodulation therapy for treatment-resistant depression: a systematic review.
Synthesis in Frontiers in psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Alleviating cognitive impairments in bipolar disorder with a novel DTI-guided multimodal neurostimulation protocol: a double-blind randomized controlled trial.BMC medicine · 2025Trial
- Magnetic Seizure Therapy vs Electroconvulsive Therapy in Schizophrenia: Prefrontal-Amygdala Plasticity and Cognitive Safety.Neuropsychiatric disease and treatment · 2025Trial
- Efficacy and Safety of Remote Ischemic Conditioning for Depression Insufficiently Responsive to Antidepressant: A Randomized Controlled Trial.Neuropsychiatric disease and treatment · 2025Trial
- A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality.Neuropsychiatric disease and treatment · 2024Trial
- Physical Therapies and Neuromodulation for Treatment-Resistant Schizophrenia: A Review of Potential Mechanisms, Efficacy, and Safety.Neuropsychiatric disease and treatment · 2026Review
- Physical Therapy for Treatment-Resistant Depression A Comprehensive Review of Efficacy, Safety, and Evidence Grading.Neuropsychiatric disease and treatment · 2026Review
- The 4977 Bp Deletion of Mitochondrial DNA as a Potential Trait Marker for Major Depressive Disorder.Neuropsychiatric disease and treatment · 2025Article
- Prevalence and Associated Factors of Depression in Patients with Ischaemic Stroke: A Cross-Sectional Study.Neuropsychiatric disease and treatment · 2025Article
- Rapid treatment center for depression in China: constructive reflections and transnational implications.Frontiers in psychiatry · 2025Review
- Disruption of Multimodal Brain Networks and Structural-Functional Coupling in Adolescents with Major Depressive Disorder.Neuropsychiatric disease and treatment · 2025Article
- Anxious Depression in Major Depressive Disorder: Key Influences and Prevalence in Chinese Hospitalized Patients.Neuropsychiatric disease and treatment · 2024Article
- Repetitive Transcranial Magnetic Stimulation Alleviates MPTP-Induced Parkinson's Disease Symptoms by Regulating CaMKII-CREB-BMAL1 Pathway in Mice Model.Neuropsychiatric disease and treatment · 2024Article
- Optimization Strategies of Transcranial Magnetic Stimulation in Major Depressive Disorder.Alpha psychiatry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This systematic review of randomized controlled studies (RCTs) and observational studies evaluated the efficacy and safety of stanford neuromodulation therapy (SNT) for patients with treatment-resistant depression (TRD). Methods: A systematic search (up to 25 September, 2023) of RCTs and single-arm prospective studies was conducted. Results: One RCT ( Conclusion: This systematic review found SNT significantly improved depressive symptoms in patients with TRD within 5 days, without severe adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.